Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Neelima Nadella

Interventional Cardiology Bay Pines, FL Medical Doctor

NPI 1043499783 CMS profile 274709

10000 Bay Pines Blvd, Bay Pines, FL 33744

Open in the dashboard

General payments

$3,148

70 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Neelima Nadella of Bay Pines, FL is reported in the CMS Open Payments database as having received $3,148 across 70 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 28th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $674 17
2024 General $487 13
2023 General $1,121 16
2022 General $221 3
2021 General $297 18
2019 General $349 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Neelima Nadella
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Neelima Nadella were reported at $674. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Neelima Nadella Interventional Cardiology median Middle half National median
2019 $349 $1,097 $329–$3,048 $163
2020 $0 $473 $161–$1,480 $114
2021 $297 $677 $233–$1,827 $132
2022 $221 $978 $333–$2,724 $149
2023 $1,121 $1,136 $382–$2,986 $160
2024 $487 $1,181 $395–$3,326 $164
2025 $674 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Shockwave Medical, Inc $418 4 payments
  2. Janssen Pharmaceuticals, Inc $364 6 payments
  3. Amgen Inc. $357 12 payments
  4. Terumo Medical Corporation $289 2 payments
  5. Philips Electronics North America Corporation $191 2 payments
  6. Boston Scientific Corporation $176 2 payments
  7. iRhythm Technologies, Inc. $175 1 payment
  8. Abiomed $159 4 payments
  9. CVRx, Inc. $154 2 payments
  10. Janssen Scientific Affairs, LLC $148 1 payment
  11. Other $718 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,148 70 payments
Products named General payments · program years 2019–2025
  1. XARELTO $511 7 payments
  2. Repatha $313 10 payments
  3. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Lithoplasty $301 3 payments
  4. ZIO Patch $175 1 payment
  5. GLIDEWIRE $164 1 payment
  6. Barostim Neo System $154 2 payments
  7. MOMENTUM $150 1 payment
  8. GLIDESHEATH SLENDER $125 1 payment
  9. (6575) Coronary Undivided $122 1 payment
  10. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Cardiology $118 1 payment
  11. Other $752 24 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,198

Median for Interventional Cardiology: 2,236

Drug cost

$138,754

Median for Interventional Cardiology: $380,412

Branded share of claims

22%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 65 $74,963
Entresto Sacubitril/Valsartan Brand 19 $22,594
Xarelto Rivaroxaban Brand 19 $14,670
Repatha Sureclick Evolocumab Brand 13 $6,909
Praluent Pen Alirocumab Brand 11 $5,193
Metoprolol Succinate Generic 200 $2,892
Atorvastatin Calcium Generic 194 $2,223
Ranolazine Er Ranolazine Brand 33 $2,134
Ezetimibe Generic 40 $1,156
Losartan Potassium Generic 85 $871

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$38,432

Medicare's payments for the services billed

Medicare patients

219

Average age 77

Services billed

553

116 women, 103 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 64%
Diabetes 52%
Heart failure 48%
Arthritis 45%
Chronic kidney disease 41%
Atrial fibrillation 39%
COPD 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $103
$103 19 —
Repatha
  • Amgen Inc. $61
$61 13 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $43
$43 — —
AMVUTTRA
  • Alnylam Pharmaceuticals Inc. $25
$25 — —
CLEVIPREX
  • CHIESI USA, INC. $12
$12 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

70 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record